ORCID as entered in ROS

Select Publications
2024, 'The cost-effectiveness of integrating simplified HCV testing into HIV pre-exposure prophylaxis (PrEP) and treatment services among men who have sex with men in Taiwan', Lancet Regional Health Western Pacific, 48, http://dx.doi.org/10.1016/j.lanwpc.2024.101119
,2024, 'Controlling COVID-19 outbreaks in the correctional setting: A mathematical modelling study', Plos One, 19, http://dx.doi.org/10.1371/journal.pone.0303062
,2024, 'Impact of simplified HCV diagnostic strategies on the HCV epidemic among men who have sex with men in the era of HIV oral pre-exposure prophylaxis in Taiwan: a modelling study', Journal of the International AIDS Society, 27, http://dx.doi.org/10.1002/jia2.26251
,2024, 'Scale-up of Direct-Acting Antiviral Treatment in Prisons Is Both Cost-effective and Key to Hepatitis C Virus Elimination', Open Forum Infectious Diseases, 11, pp. ofad637, http://dx.doi.org/10.1093/ofid/ofad637
,2024, 'Corrigendum: Preparing correctional settings for the next pandemic: a modeling study of COVID-19 outbreaks in two high-income countries (Frontiers in Public Health, (2024), 12, (1279572), 10.3389/fpubh.2024.1279572)', Frontiers in Public Health, 12, http://dx.doi.org/10.3389/fpubh.2024.1478843
,2024, 'Preparing correctional settings for the next pandemic: a modeling study of COVID-19 outbreaks in two high-income countries', Frontiers in Public Health, 12, http://dx.doi.org/10.3389/fpubh.2024.1279572
,2023, 'Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study', Lancet Gastroenterology and Hepatology, 8, pp. 879 - 907, http://dx.doi.org/10.1016/S2468-1253(23)00197-8
,2023, 'Optimizing point-of-care testing strategies for diagnosis and treatment of hepatitis C virus infection in Australia: a model-based cost-effectiveness analysis', Lancet Regional Health Western Pacific, 36, pp. 100750, http://dx.doi.org/10.1016/j.lanwpc.2023.100750
,2023, 'Removing hepatitis C antibody testing for Australian blood donations: A cost-effectiveness analysis', Vox Sanguinis, 118, pp. 471 - 479, http://dx.doi.org/10.1111/vox.13429
,2022, 'Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study', Lancet Gastroenterology and Hepatology, 7, pp. 396 - 415, http://dx.doi.org/10.1016/S2468-1253(21)00472-6
,2022, 'Lifetime cost of HIV management in Australia: an economic model', Sexual Health, 19, http://dx.doi.org/10.1071/SH21250
,2021, 'Australia could miss the WHO hepatitis C virus elimination targets due to declining treatment uptake and ongoing burden of advanced liver disease complications', Plos One, 16, http://dx.doi.org/10.1371/journal.pone.0257369
,2021, 'Hepatitis C treatment strategies in prisons: A cost-effectiveness analysis', Plos One, 16, pp. e0245896, http://dx.doi.org/10.1371/journal.pone.0245896
,2020, 'Assessment of Treatment Strategies to Achieve Hepatitis C Elimination in Canada Using a Validated Model', JAMA Network Open, 3, http://dx.doi.org/10.1001/jamanetworkopen.2020.4192
,2019, 'Estimating the number of people who inject drugs and syringe coverage in Australia, 2005–2016', Drug and Alcohol Dependence, 197, pp. 108 - 114, http://dx.doi.org/10.1016/j.drugalcdep.2018.11.033
,2019, 'Australia on track to achieve WHO HCV elimination targets following rapid initial DAA treatment uptake: A modelling study', Journal of Viral Hepatitis, 26, pp. 83 - 92, http://dx.doi.org/10.1111/jvh.13013
,2012, 'Estimating the cost-effectiveness of needle-syringe programs in Australia.', AIDS, 26, pp. 2201 - 2210, http://dx.doi.org/10.1097/QAD.0b013e3283578b5d
,2009, 'The impact of needle and syringe programs on HIV and HCV transmissions in injecting drug users in Australia: A model-based analysis', JAIDS: Journal of Acquired Immune Deficiency Syndromes, 51, pp. 462 - 469, http://dx.doi.org/10.1097/QAI.0b013e3181a2539a
,2009, 'What impact might the economic crisis have on HIV epidemics in Southeast Asia?', Current HIV Research, 7, pp. 656 - 665, http://dx.doi.org/10.2174/157016209789973637
,